Ziftomenib

The KOMET-001 study, led by Roswell Park, tested ziftomenib, a menin inhibitor, in AML patients with prior therapies. Published in The Lancet Oncology, it showed partial or complete response in about a third of patients, particularly those with NPM1 mutations or KMT2A rearrangements. The FDA granted Breakthrough Therapy designation to ziftomenib, and additional trials are underway at Roswell Park.

The article discusses AML treatment advancements, emphasizing the 7 + 3 regimen's evolution with high-dose cytarabine, nucleoside analogs, and targeted therapies like venetoclax and FLT3 inhibitors. It highlights improved outcomes with intensive chemotherapy combinations and the potential of allogeneic HSCT in first remission for intermediate-high risk AML.

Kura Oncology appoints Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles brings over 25 years of oncology drug development experience and leadership. He is currently a Senior Advisor at Frazier Healthcare Partners and has held senior roles at ImmunoGen, Flatiron Health, Unum Therapeutics, Takeda/Millennium, and Genzyme Corporation. Dr. Vasconcelles expressed enthusiasm for Kura's precision oncology approach and its menin inhibitor program for acute leukemias.

Kura Oncology (KURA) is a clinical-stage biopharmaceutical company developing precision medicines for cancer, with key candidates like Tipifarnib, Ziftomenib, and KO-2806. Recent achievements include preliminary data from the KOMET-007 trial and securing financing through 2027.

Kura Oncology's ziftomenib, combined with imatinib, shows potential to resensitize advanced GIST patients to imatinib, inducing durable responses. A Phase 1 study is set for early 2025, following FDA IND clearance. Preclinical data supports the combination's efficacy in imatinib-resistant models.

Bank of America's Savita Subramanian advises against Warren Buffet's index fund strategy, recommending small-cap value stocks instead for higher returns. Highlighted stocks include RAPT Therapeutics and Kura Oncology, both with strong buy ratings and significant upside potential, focusing on innovative treatments in biotech.